Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1998 Jan;51(1):5–12. doi: 10.1136/jcp.51.1.5

Pathological changes in prostate lesions after androgen manipulation.

R Montironi 1, C C Schulman 1
PMCID: PMC500422  PMID: 9577363

Abstract

The number of newly diagnosed cases of prostate cancer has doubled in the past four years because of the aging of the population coupled with growing awareness of the importance of early detection. The issues of clinical understaging and resection limit positivity have led to the development of novel management practices, including neoadjuvant hormonal treatment, which aims to downstage the primary tumour and decrease the positive margin rate before definitive localised treatment (radical prostatectomy or definitive radiation treatment (neoadjuvant)). There is conflicting evidence regarding pathological downstaging, with some studies suggesting benefit and others no benefit of androgen manipulation before radical prostatectomy. The problem might be related to incomplete sampling of the prostates and difficulties associated with the pathological interpretation of morphological changes. The least controversial aspect of neoadjuvant treatment is its impact on surgical margins. Most series have shown that neoadjuvant treatment in clinical T2 tumours is associated with a 20-25% decrease in positive margins in radical prostatectomy specimens. In patients with clinical T3 tumours, the effects of neoadjuvant treatment on positive margins are less clear. Even if some early significant advantages can be observed following hormonal treatment this may not alter the metastatic spread and overall survival rate. Only long term follow up studies evaluating biological and clinical failures, time to progression, and survival will allow definitive conclusions from this approach.

Full text

PDF
5

Images in this article

7Image
on p.7
7Image
on p.7
8Image
on p.8
8Image
on p.8
9Image
on p.9
9Image
on p.9

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbas F., Scardino P. T. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am. 1996 Nov;23(4):587–604. doi: 10.1016/s0094-0143(05)70338-4. [DOI] [PubMed] [Google Scholar]
  2. Akakura K., Bruchovsky N., Goldenberg S. L., Rennie P. S., Buckley A. R., Sullivan L. D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993 May 1;71(9):2782–2790. doi: 10.1002/1097-0142(19930501)71:9<2782::aid-cncr2820710916>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  3. Armas O. A., Aprikian A. G., Melamed J., Cordon-Cardo C., Cohen D. W., Erlandson R., Fair W. R., Reuter V. E. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol. 1994 Oct;18(10):979–991. doi: 10.1097/00000478-199410000-00002. [DOI] [PubMed] [Google Scholar]
  4. Bazinet M., Zheng W., Bégin L. R., Aprikian A. G., Karakiewicz P. I., Elhilali M. M. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology. 1997 May;49(5):721–725. doi: 10.1016/S0090-4295(97)00062-9. [DOI] [PubMed] [Google Scholar]
  5. Bostwick D. G., Myers R. P., Oesterling J. E. Staging of prostate cancer. Semin Surg Oncol. 1994 Jan-Feb;10(1):60–72. doi: 10.1002/ssu.2980100110. [DOI] [PubMed] [Google Scholar]
  6. Bostwick D. G. Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol. 1996;30(2):145–152. doi: 10.1159/000474164. [DOI] [PubMed] [Google Scholar]
  7. Catalona W. J., Smith D. S., Ratliff T. L., Dodds K. M., Coplen D. E., Yuan J. J., Petros J. A., Andriole G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156–1161. doi: 10.1056/NEJM199104253241702. [DOI] [PubMed] [Google Scholar]
  8. Civantos F., Soloway M. S., Pinto J. E. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol. 1996 May;14(2 Suppl 2):22–31. [PubMed] [Google Scholar]
  9. Epstein J. I., Pizov G., Walsh P. C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993 Jun 1;71(11):3582–3593. doi: 10.1002/1097-0142(19930601)71:11<3582::aid-cncr2820711120>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  10. Fair W. R., Aprikian A., Sogani P., Reuter V., Whitmore W. F., Jr The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer. 1993 Feb 1;71(3 Suppl):1031–1038. doi: 10.1002/1097-0142(19930201)71:3+<1031::aid-cncr2820711422>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  11. Fair W. R., Cookson M. S., Stroumbakis N., Cohen D., Aprikian A. G., Wang Y., Russo P., Soloway S. M., Sogani P., Sheinfeld J. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology. 1997 Mar;49(3A):46–55. doi: 10.1016/s0090-4295(97)00169-6. [DOI] [PubMed] [Google Scholar]
  12. Ferguson J., Zincke H., Ellison E., Bergstrahl E., Bostwick D. G. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology. 1994 Jul;44(1):91–95. doi: 10.1016/s0090-4295(94)80015-4. [DOI] [PubMed] [Google Scholar]
  13. Gleave M. E., Goldenberg S. L., Jones E. C., Bruchovsky N., Kinahan J., Sullivan L. D. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Semin Urol Oncol. 1996 May;14(2 Suppl 2):39–47. [PubMed] [Google Scholar]
  14. Gleave M. E., Goldenberg S. L., Jones E. C., Bruchovsky N., Sullivan L. D. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol. 1996 Jan;155(1):213–219. [PubMed] [Google Scholar]
  15. Goldenberg S. L., Klotz L. H., Srigley J., Jewett M. A., Mador D., Fradet Y., Barkin J., Chin J., Paquin J. M., Bullock M. J. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol. 1996 Sep;156(3):873–877. [PubMed] [Google Scholar]
  16. Gould V. E., Doljanskaia V., Gooch G. T., Bostwick D. G. Stability of the glycoprotein A-80 in prostatic carcinoma subsequent to androgen deprivation therapy. Am J Surg Pathol. 1997 Mar;21(3):319–326. doi: 10.1097/00000478-199703000-00008. [DOI] [PubMed] [Google Scholar]
  17. Häggman M., Hellström M., Aus G., Pedersen K., Wijkström H., Stege R., Elvin A., Tisell A., de la Torre M., Busch C. Neoadjuvant GnRH-agonist treatment (triptorelin and cyproterone acetate for flare protection) and total prostatectomy. Eur Urol. 1993;24(4):456–460. doi: 10.1159/000474349. [DOI] [PubMed] [Google Scholar]
  18. Magi Galluzzi C., Montironi R., Giannulis I., Diamanti L., Scarpelli M., Muzzonigro G., Polito M. Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA). Pathol Res Pract. 1993 Dec;189(10):1154–1160. doi: 10.1016/S0344-0338(11)80838-1. [DOI] [PubMed] [Google Scholar]
  19. Montironi R., Bartels P. H., Thompson D., Diamanti L., Prete E. Androgen-deprived prostate adenocarcinoma: evaluation of treatment-related changes versus no distinctive treatment effect with a Bayesian belief network. A methodological approach. Eur Urol. 1996;30(3):307–315. doi: 10.1159/000474188. [DOI] [PubMed] [Google Scholar]
  20. Montironi R., Magi Galluzzi C. M., Marina S., Diamanti L. Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. J Cell Biochem Suppl. 1994;19:238–245. [PubMed] [Google Scholar]
  21. Montironi R., Magi-Galluzzi C., Fabris G. Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathol Res Pract. 1995 Sep;191(9):873–880. doi: 10.1016/s0344-0338(11)80971-4. [DOI] [PubMed] [Google Scholar]
  22. Montironi R., Magi-Galluzzi C., Muzzonigro G., Prete E., Polito M., Fabris G. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J Clin Pathol. 1994 Oct;47(10):906–913. doi: 10.1136/jcp.47.10.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Murphy W. M., Soloway M. S., Barrows G. H. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer. 1991 Aug 15;68(4):821–828. doi: 10.1002/1097-0142(19910815)68:4<821::aid-cncr2820680426>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  24. Ohori M., Wheeler T. M., Kattan M. W., Goto Y., Scardino P. T. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995 Nov;154(5):1818–1824. [PubMed] [Google Scholar]
  25. Paulson D. F. Impact of radical prostatectomy in the management of clinically localized disease. J Urol. 1994 Nov;152(5 Pt 2):1826–1830. doi: 10.1016/s0022-5347(17)32395-9. [DOI] [PubMed] [Google Scholar]
  26. Reuter V. E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology. 1997 Mar;49(3A):16–22. doi: 10.1016/s0090-4295(97)00164-7. [DOI] [PubMed] [Google Scholar]
  27. Schulman C. C. Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review. Prostate Suppl. 1994;5:9–14. doi: 10.1002/pros.2990250705. [DOI] [PubMed] [Google Scholar]
  28. Schulman C. C., Sassine A. M. Neoadjuvant hormonal deprivation before radical prostatectomy. Eur Urol. 1993;24(4):450–455. doi: 10.1159/000474348. [DOI] [PubMed] [Google Scholar]
  29. Schulman C. C., Wildschutz T., Zlotta A. R. Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and open questions. Eur Urol. 1997;32 (Suppl 3):41–47. [PubMed] [Google Scholar]
  30. Smith D. M., Murphy W. M. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer. 1994 Mar 1;73(5):1472–1477. doi: 10.1002/1097-0142(19940301)73:5<1472::aid-cncr2820730525>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  31. Soloway M. S., Sharifi R., Wajsman Z., McLeod D., Wood D. P., Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 1995 Aug;154(2 Pt 1):424–428. [PubMed] [Google Scholar]
  32. Têtu B., Srigley J. R., Boivin J. C., Dupont A., Monfette G., Pinault S., Labrie F. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol. 1991 Feb;15(2):111–120. doi: 10.1097/00000478-199102000-00002. [DOI] [PubMed] [Google Scholar]
  33. Van de Voorde W. M., Elgamal A. A., Van Poppel H. P., Verbeken E. K., Baert L. V., Lauweryns J. M. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer. 1994 Dec 15;74(12):3164–3175. doi: 10.1002/1097-0142(19941215)74:12<3164::aid-cncr2820741216>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  34. Watson R. B., Soloway M. S. Neoadjuvant hormonal treatment before radical prostatectomy. Semin Urol Oncol. 1996 May;14(2 Suppl 2):48–56. [PubMed] [Google Scholar]
  35. Wojno K. J., Epstein J. I. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol. 1995 Mar;19(3):251–260. doi: 10.1097/00000478-199503000-00002. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES